PubRank

David R Gastfriend

Author PubWeight™ 59.13‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 2006 13.15
2 Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet 2011 6.35
3 Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial. JAMA 2005 4.64
4 Addiction denial and cognitive dysfunction: a preliminary investigation. J Neuropsychiatry Clin Neurosci 2002 1.76
5 Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. Addiction 2013 1.63
6 The relationship between cocaine craving, psychosocial treatment, and subsequent cocaine use. Am J Psychiatry 2003 1.63
7 The effect of 12-step self-help group attendance and participation on drug use outcomes among cocaine-dependent patients. Drug Alcohol Depend 2005 1.55
8 Physician substance abuse and recovery: what does it mean for physicians--and everyone else? JAMA 2005 1.53
9 Efficacy of extended-release naltrexone in alcohol-dependent patients who are abstinent before treatment. J Clin Psychopharmacol 2007 1.42
10 Decreased absolute amygdala volume in cocaine addicts. Neuron 2004 1.41
11 Retention in psychosocial treatment of cocaine dependence: predictors and impact on outcome. Am J Addict 2002 1.12
12 Persistence with oral naltrexone for alcohol treatment: implications for health-care utilization. Addiction 2008 1.12
13 Prevalence of physical and sexual abuse among substance abuse patients and impact on treatment outcomes. Drug Alcohol Depend 2004 1.07
14 Cost and utilization outcomes of opioid-dependence treatments. Am J Manag Care 2011 1.03
15 Advancing performance measures for use of medications in substance abuse treatment. J Subst Abuse Treat 2010 1.03
16 Alcohol dependence treatments: comprehensive healthcare costs, utilization outcomes, and pharmacotherapy persistence. Am J Manag Care 2011 0.99
17 Factorial designs in clinical trials: options for combination treatment studies. J Stud Alcohol Suppl 2005 0.97
18 Opioid challenge evaluation of blockade by extended-release naltrexone in opioid-abusing adults: dose-effects and time-course. Drug Alcohol Depend 2011 0.95
19 Comparison of healthcare utilization among patients treated with alcoholism medications. Am J Manag Care 2010 0.93
20 Cocaine-primed craving and its relationship to depressive symptomatology in individuals with cocaine dependence. J Psychopharmacol 2002 0.90
21 Design and analysis of trials of combination therapies. J Stud Alcohol Suppl 2005 0.90
22 Effect of extended-release naltrexone (XR-NTX) on quality of life in alcohol-dependent patients. Alcohol Clin Exp Res 2008 0.90
23 Long-term opioid blockade and hedonic response: preliminary data from two open-label extension studies with extended-release naltrexone. Am J Addict 2010 0.88
24 Validation of the Addiction Severity Index (ASI) for internet and automated telephone self-report administration. J Subst Abuse Treat 2004 0.86
25 No-Show for Treatment in Substance Abuse Patients with Comorbid Symptomatology: Validity Results from a Controlled Trial of the ASAM Patient Placement Criteria. J Addict Med 2007 0.86
26 Injectable extended-release naltrexone for opioid dependence. Lancet 2011 0.83
27 Effects of injectable extended-release naltrexone (XR-NTX) for opioid dependence on residential rehabilitation outcomes and early follow-up. Am J Addict 2015 0.82
28 Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX): Who Will Respond? J Addict Med 2015 0.81
29 Early treatment response in alcohol dependence with extended-release naltrexone. J Clin Psychiatry 2008 0.79
30 Determining service variations between and within ASAM levels of care. J Addict Dis 2003 0.79
31 Effects of naltrexone treatment for alcohol-related disorders on healthcare costs in an insured population. Alcohol Clin Exp Res 2010 0.79
32 Efficacy of extended-release naltrexone in patients with relatively higher severity of alcohol dependence. Alcohol Clin Exp Res 2011 0.79
33 Predictive validity of the ASAM Patient Placement Criteria for hospital utilization. J Addict Dis 2003 0.78
34 Impact of treatment with intramuscular, injectable, extended-release naltrexone on counseling and support group participation in patients with alcohol dependence. J Addict Med 2010 0.77
35 Overriding the blockade of antinociceptive actions of opioids in rats treated with extended-release naltrexone. Pharmacol Biochem Behav 2008 0.77
36 Reliability of multidimensional substance abuse treatment matching: implementing the ASAM Patient Placement Criteria. J Addict Dis 2003 0.77
37 The ASAM patient placement criteria: context, concepts and continuing development. J Addict Dis 2003 0.76
38 Olanzapine-induced hyperventilation: case report. J Psychiatry Neurosci 2002 0.75
39 Advances in the pharmacotherapy of alcoholism: challenging misconceptions. Alcohol Clin Exp Res 2006 0.75
40 Visual inspection of medications in preventing unexplained relapses. Ann Pharmacother 2002 0.75
41 Open-label Study of Injectable Extended-release Naltrexone (XR-NTX) in Healthcare Professionals With Opioid Dependence. J Addict Med 2017 0.75